Literature DB >> 17021640

Monitoring response, prediction methodology, staging, and imaging in prostate cancer.

David Pomerantz, Nicholas Vogelzang.   

Abstract

The predictive values of various tests and examinations are assessed as they relate to prostate cancer progression and treatment. The usefulness of post-treatment biopsy specimens is greatest 2 years after radiation therapy completion. Gleason grading is not reliable in the setting of hormonal ablation therapy. For patients with extracapsular extension, the survival curves separate depending on whether positive or negative surgical margins are obtained. Prostate-specific antigen doubling time is increasingly used as an indicator of disease recurrence after local therapy and prostate cancer-specific survival.

Entities:  

Year:  2006        PMID: 17021640      PMCID: PMC1578716     

Source DB:  PubMed          Journal:  Rev Urol        ISSN: 1523-6161


  15 in total

1.  Retrospective analysis of prostate cancer patients with implanted gold markers using off-line and adaptive therapy protocols.

Authors:  Dale W Litzenberg; James M Balter; Kwok L Lam; Howard M Sandler; Randall K Ten Haken
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-09-01       Impact factor: 7.038

2.  Survival in prostate carcinoma--outcomes from a prospective, population-based cohort of 8887 men with up to 15 years of follow-up: results from three countries in the population-based National Prostate Cancer Registry of Sweden.

Authors:  Gunnar Aus; David Robinson; Johan Rosell; Gabriel Sandblom; Eberhard Varenhorst
Journal:  Cancer       Date:  2005-03-01       Impact factor: 6.860

3.  Comparison of clinical staging algorithms and 111indium-capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients.

Authors:  T J Polascik; M J Manyak; M K Haseman; R T Gurganus; B Rogers; R T Maguire; A W Partin
Journal:  Cancer       Date:  1999-04-01       Impact factor: 6.860

4.  Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

Authors:  P W Kantoff; S Halabi; M Conaway; J Picus; J Kirshner; V Hars; D Trump; E P Winer; N J Vogelzang
Journal:  J Clin Oncol       Date:  1999-08       Impact factor: 44.544

5.  Surrogate end point for prostate cancer specific mortality in patients with nonmetastatic hormone refractory prostate cancer.

Authors:  Anthony V D'Amico; Judd Moul; Peter R Carroll; Leon Sun; Deborah Lubeck; Ming-Hui Chen
Journal:  J Urol       Date:  2005-05       Impact factor: 7.450

Review 6.  Pathological changes in benign and malignant prostatic tissue following androgen deprivation therapy.

Authors:  V E Reuter
Journal:  Urology       Date:  1997-03       Impact factor: 2.649

7.  Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results.

Authors:  Kimberly A Roehl; Misop Han; Christian G Ramos; Jo Ann V Antenor; William J Catalona
Journal:  J Urol       Date:  2004-09       Impact factor: 7.450

8.  Validation of increasing prostate specific antigen as a predictor of prostate cancer death after treatment of localized prostate cancer with surgery or radiation.

Authors:  Peter C Albertsen; James A Hanley; David F Penson; Judith Fine
Journal:  J Urol       Date:  2004-06       Impact factor: 7.450

9.  Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure.

Authors:  Anthony V D'Amico; Judd W Moul; Peter R Carroll; Kerri Cote; Leon Sun; Deborah Lubeck; Andrew A Renshaw; Marian Loffredo; Ming-Hui Chen
Journal:  J Natl Cancer Inst       Date:  2004-04-07       Impact factor: 13.506

10.  Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02.

Authors:  Gerald E Hanks; Thomas F Pajak; Arthur Porter; David Grignon; Harmart Brereton; Varagur Venkatesan; Eric M Horwitz; Colleen Lawton; Seth A Rosenthal; Howard M Sandler; William U Shipley
Journal:  J Clin Oncol       Date:  2003-11-01       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.